Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gaetane Nocturne

Showing results (1-10 of 94) with videos related to

Pageof 10
Sort By:
The Lancet. Rheumatology|May 20, 2026
Leflunomide-hydroxychloroquine: a replicable hope in Sjögren's disease?Gaetane Nocturne
RMD Open|January 4, 2023
Interferon signature in systemic autoimmune diseases: what does it mean?Gaetane Nocturne, Xavier Mariette
Arthritis & Rheumatology (Hoboken, N.J.)|May 25, 2023
Expert Perspective: Challenges in Sjögren's DiseaseGaetane Nocturne, Xavier Mariette
La Revue Du Praticien|October 5, 2023
[Inflammatory diseases of the salivary]Gaetane Nocturne, Marjolaine Gosset
British Journal of Haematology|October 16, 2014
Sjögren Syndrome-associated lymphomas: an update on pathogenesis and managementGaetane Nocturne, Xavier Mariette
Arthritis & Rheumatology (Hoboken, N.J.)|January 11, 2016
ReplyGaetane Nocturne, Raphaèle Seror, Xavier Mariette
Annals of the Rheumatic Diseases|October 16, 2016
Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?Gaetane Nocturne, Raphaele Seror, Xavier Mariette
Journal of Clinical Medicine|March 14, 2026
Update on the Aetiopathogenesis of Sjögren Disease: From Interferon Signaling to Epithelial DysfunctionLoïc Meudec, Gaetane Nocturne, Xavier Mariette
Annals of the Rheumatic Diseases|October 16, 2020
Response to: 'Role of interaction between B cells and epithelial cells in pSS' by Pringle <i>et al</i>Elodie Rivière, Xavier Mariette, Gaetane Nocturne
Nature Reviews. Rheumatology|June 30, 2021
Current and future therapies for primary Sjögren syndromeRaphaèle Seror, Gaetane Nocturne, Xavier Mariette
Pageof 10

Showing results (1-10 of 94) with videos related to

Sort By:
Pageof 10
The Lancet. Rheumatology|May 20, 2026
Leflunomide-hydroxychloroquine: a replicable hope in Sjögren's disease?Gaetane Nocturne
RMD Open|January 4, 2023
Interferon signature in systemic autoimmune diseases: what does it mean?Gaetane Nocturne, Xavier Mariette
Arthritis & Rheumatology (Hoboken, N.J.)|May 25, 2023
Expert Perspective: Challenges in Sjögren's DiseaseGaetane Nocturne, Xavier Mariette
La Revue Du Praticien|October 5, 2023
[Inflammatory diseases of the salivary]Gaetane Nocturne, Marjolaine Gosset
British Journal of Haematology|October 16, 2014
Sjögren Syndrome-associated lymphomas: an update on pathogenesis and managementGaetane Nocturne, Xavier Mariette
Arthritis & Rheumatology (Hoboken, N.J.)|January 11, 2016
ReplyGaetane Nocturne, Raphaèle Seror, Xavier Mariette
Annals of the Rheumatic Diseases|October 16, 2016
Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?Gaetane Nocturne, Raphaele Seror, Xavier Mariette
Journal of Clinical Medicine|March 14, 2026
Update on the Aetiopathogenesis of Sjögren Disease: From Interferon Signaling to Epithelial DysfunctionLoïc Meudec, Gaetane Nocturne, Xavier Mariette
Annals of the Rheumatic Diseases|October 16, 2020
Response to: 'Role of interaction between B cells and epithelial cells in pSS' by Pringle <i>et al</i>Elodie Rivière, Xavier Mariette, Gaetane Nocturne
Nature Reviews. Rheumatology|June 30, 2021
Current and future therapies for primary Sjögren syndromeRaphaèle Seror, Gaetane Nocturne, Xavier Mariette
Pageof 10